Article
Clinical Neurology
Irep Uras, Merve Karayel-Basar, Betul Sahin, Ahmet Tarik Baykal
Summary: Alzheimer's disease (AD) is a debilitating neurodegenerative disorder characterized by memory deficit and dementia. In this study, the spatial proteomic differences in the neonatal 5xFAD brain tissue were investigated using MALDI-MSI coupled to LC-MS/MS, and the differentially expressed proteins (DEPs) associated with AD were identified. The results showed a remarkable resemblance in the protein expression profiles of neonatal 5xFAD brain compared to AD patient specimens or AD mouse models, suggesting that molecular alterations in the AD brain existed even at birth and certain proteins may serve as neurodegenerative presages in neonatal AD brain.
ALZHEIMERS & DEMENTIA
(2023)
Article
Chemistry, Analytical
Jia Yi, Yueqing Shen, Yi Yang, Chengpin Shen, Baohong Liu, Liang Qiao, Yan Wang
Summary: By characterizing gingival crevicular fluid (GCF) sediments and identifying potential protein biomarkers using mass spectrometry techniques, this study has contributed to the early diagnosis of periodontitis and understanding of its pathogenesis. The identified biomarkers hold potential value for accurate monitoring and can be utilized by non-specialists for widespread screening.
Article
Cell & Tissue Engineering
Yejoo Choi, Sungho Shin, Hyo Jin Son, Na-Hee Lee, Su Hyeon Myeong, Cheolju Lee, Hyemin Jang, Soo Jin Choi, Hee Jin Kim, Duk L. Na
Summary: This study identified two proteins (RCN3 and FSTL3) that may be potential biomarkers for predicting the response to MSCs in AD patients, and four proteins (SCRG1, NPDC1, ApoE, and CysC) that may be potential biomarkers for monitoring the response to MSCs in AD patients.
STEM CELL RESEARCH & THERAPY
(2023)
Review
Biochemistry & Molecular Biology
Weifu Ren, Qi Bian, Yan Cai
Summary: Kidney disease is a global health concern that requires upgraded diagnostic tools to diagnose and prevent disease progression at an early stage. N-glycosylation, as an important protein modification, plays a crucial role in renal structure and function. Research on the role of N-glycosylation in kidney disease provides insights into its pathophysiology and paves the way for clinical applications.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2022)
Article
Chemistry, Analytical
Yanwen Chen, Dejun Hu, Lisha Zhao, Weiwei Tang, Bin Li
Summary: This study developed a novel MALDI matrix for improved evaluation of metabolic alterations in the brain and serum of an AD mouse model. The research found that 93 metabolites in the brain and 81 metabolites in the serum exhibited changes in AD mice compared to the control group. The application of this method can enhance our understanding of the etiopathogenesis of AD.
ANALYTICA CHIMICA ACTA
(2022)
Review
Chemistry, Analytical
Negin Fasih Ramandi, Mohammad Faranoush, Alireza Ghassempour, Hassan Y. Aboul-Enein
Summary: The recent success in studying the proteome as a source of biomarkers has revolutionized our understanding of leukemia. The use of mass spectrometry techniques to identify differentially expressed proteins has led to improved diagnosis, prognosis, and treatment strategies for leukemia. This review focuses on the use of various ionization sources and mass analyzers in monitoring different types of leukemia, with MALDI-TOF MS identified as a quick and reliable method for protein analysis. Additionally, the review classifies over 400 proteins and identifies specific biomarkers for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and other stages of leukemia for future studies.
CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY
(2022)
Article
Chemistry, Analytical
Liang Shan, Han Gao, Jing Zhang, Wentao Li, Yue Su, Yinlong Guo
Summary: This study combined MALDI-TOF MS with EM technology to directly analyze exosomal proteins in human plasma and serum. The results showed that EM had higher sensitivity in the high-mass range and characteristic exosomal proteins were identified. Furthermore, when using EM as a detector, there was a good linear relationship between peak intensity and concentration.
Article
Biochemistry & Molecular Biology
Wenjing Li, Yinhua Zhou, Zhaofan Luo, Rixin Tang, Yuxuan Sun, Qiangsheng He, Bin Xia, Kuiqing Lu, Qinghua Hou, Jinqiu Yuan
Summary: This study aims to construct a lipid score system to predict the risk of progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD). The results showed that the lipid score system based on serum lipidomics can accurately predict the progression risk from MCI to AD.
Article
Neurosciences
Malin Wennstrom, Shorena Janelidze, K. Peter R. Nilsson, Geidy E. Serrano, Thomas G. Beach, Jeffrey L. Dage, Oskar Hansson
Summary: Recent studies have identified p-tau217 as a potential plasma biomarker for Alzheimer's disease (AD), but its relationship with specific brain pathological events is still unclear. This study found that p-tau217 is mainly found in neurofibrillary tangles and neuropil threads, and differs from other p-tau variants. Individuals with a high likelihood of AD had significantly higher p-tau217 levels in specific brain areas and these levels correlated with amyloid-beta and NFT brain load. Additionally, the levels of p-tau217 in plasma correlated with its concentrations in individuals with amyloid plaques.
ACTA NEUROPATHOLOGICA COMMUNICATIONS
(2022)
Article
Biochemical Research Methods
Yang Zang, Xirui Zhou, Mengyun Pan, Yanli Lu, Hangrui Liu, Jinping Xiong, Liuxing Feng
Summary: Alzheimer's disease (AD) is an emerging neurodegenerative disease and a leading cause of dementia in older adults. Visinin-like protein-1 (VILIP-1) has been increasingly used as a biomarker for AD. However, there are significant variations in the commercial immuno-based assays for VILIP-1 quantification, highlighting the need for traceability. In this study, a VILIP-1 solution CRM with certified values and great stability was developed and showed potential in early diagnosis and disease monitoring for AD.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY
(2023)
Article
Geriatrics & Gerontology
Aladdin H. Shadyab, Linda K. McEvoy, Steve Horvath, Eric A. Whitsel, Stephen R. Rapp, Mark A. Espeland, Susan M. Resnick, JoAnn E. Manson, Jiu-Chiuan Chen, Brian H. Chen, Wenjun Li, Kathleen M. Hayden, Wei Bao, Cynthia D. J. Kusters, Andrea Z. LaCroix
Summary: The study examined the association between epigenetic age acceleration and cognitive impairment, finding that intrinsic AgeAccel was not significantly associated with cognitive impairment overall, but was associated with impairment among women who developed coronary heart disease.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
(2022)
Article
Medicine, General & Internal
Longfei Jia, Min Zhu, Jianwei Yang, Yana Pang, Qi Wang, Ying Li, Tingting Li, Fangyu Li, Qigeng Wang, Yan Li, Yiping Wei
Summary: This study suggests that a panel of microRNAs in serum can serve as a promising substitute for traditional measurement of P-tau/A beta 42 in CSF as an effective biomarker of Alzheimer's disease (AD), successfully differentiating AD from other dementias.
Article
Pharmacology & Pharmacy
Zhao Dai, Tian Hu, Shijie Su, Jinman Liu, Yinzhong Ma, Yue Zhuo, Shuhuan Fang, Qi Wang, Zhizhun Mo, Huafeng Pan, Jiansong Fang
Summary: This study conducted a comprehensive metabolomics analysis on AD animal models and patients, revealing key metabolites and pathways, and predicting potential protein markers. The findings are of great significance for understanding the pathological mechanism of AD.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Francesca Romana Buccellato, Marianna D'Anca, Chiara Fenoglio, Elio Scarpini, Daniela Galimberti
Summary: Alzheimer's disease is a neurodegenerative disorder with no effective treatments, emphasizing the importance of discovering biomarkers for early diagnosis. Oxidative damage is involved in the molecular mechanisms linking amyloid-beta and hyperphosphorylated tau to microglia response, playing a crucial role in the pathogenesis of AD and neurodegeneration.
Article
Clinical Neurology
Jun Wang, Ming Chen, Colin L. L. Masters, Yan-Jiang Wang
Summary: Early and accurate diagnosis of Alzheimer's disease (AD) is crucial for effective treatment. Blood biomarker assays are a promising tool for clinical diagnosis due to their non-invasive nature, cost-effectiveness, and accessibility. However, challenges in using blood biomarkers for AD diagnosis in community-based populations include confounding factors, small changes in biomarker levels, and difficulty in detecting early changes. This article analyzes these challenges and provides perspectives on strategies to overcome them, facilitating the translation of blood biomarker research into clinical practice.
ALZHEIMERS & DEMENTIA
(2023)
Article
Medical Laboratory Technology
Kaj Blennow, Erik Stomrud, Henrik Zetterberg, Niels Borlinghaus, Veronika Corradini, Ekaterina Manuilova, Laura Muller-Hubner, Frances-Catherine Quevenco, Sandra Rutz, Oskar Hansson
Summary: This study evaluated the analytical performance of second-generation Elecsys CSF Gen II immunoassays and adjusted existing cut-offs to evaluate their potential utility in clinical routine. The findings suggest that the Gen II immunoassays have potential utility in aiding the diagnosis of Alzheimer's disease.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Article
Clinical Neurology
Isabelle Glans, Emily Sonestedt, Katarina Nagga, Anna-Marta Gustavsson, Esther Gonzalez-Padilla, Yan Borne, Erik Stomrud, Olle Melander, Peter M. Nilsson, Sebastian Palmqvist, Oskar Hansson
Summary: This study aimed to investigate whether adherence to conventional dietary recommendations or to a modified Mediterranean diet are associated with a subsequent lower risk of developing all-cause dementia, Alzheimer disease (AD), vascular dementia (VaD), or with future accumulation of AD-related beta-amyloid (A beta) pathology. The results showed that adherence to either conventional dietary recommendations or a modified Mediterranean diet did not significantly lower the risk of developing dementia or AD pathology.
Article
Clinical Neurology
Kevin Oliveira Hauer, Daria Pawlik, Antoine Leuzy, Shorena Janelidze, Sara Hall, Oskar Hansson, Ruben Smith
Summary: This study aimed to evaluate the ability of three different biomarkers ([F-18]RO948 PET, MRI midbrain/pons ratio, and cerebrospinal fluid neurofilament light) to distinguish patients with progressive supranuclear palsy (PSP) from healthy controls and alpha-synucleinopathies patients. The results showed that these biomarkers could effectively differentiate these different patient groups at a group level.
PARKINSONISM & RELATED DISORDERS
(2023)
Article
Clinical Neurology
Niklas Mattsson-Carlgren, Gemma Salvado, Nicholas J. Ashton, Pontus Tideman, Erik Stomrud, Henrik Zetterberg, Rik Ossenkoppele, Tobey J. Betthauser, Karly Alex Cody, Erin M. Jonaitis, Rebecca Langhough, Sebastian Palmqvist, Kaj Blennow, Shorena Janelidze, Sterling C. Johnson, Oskar Hansson
Summary: Plasma P-tau217 can predict cognitive decline in patients with preclinical AD, suggesting it may be used as a complement to CSF or PET for participant selection in clinical trials.
Article
Clinical Neurology
C. Mallinckrodt, Y. Tian, P. S. Aisen, F. Barkhof, S. Cohen, G. Dent, O. Hansson, K. Harrison, T. Iwatsubo, C. J. Mummery, K. K. Muralidharan, I. Nestorov, L. Nisenbaum, R. Rajagovindan, C. von Hehn, C. H. van Dyck, B. Vellas, S. Wu, Y. Zhu, A. Sandrock, T. Chen, S. Budd Haeberlein
Summary: Post-hoc analyses of the EMERGE and ENGAGE studies showed that the outcomes in the high-dose group of ENGAGE were affected by an imbalance in a small number of rapidly progressing patients and lower exposure to the target dose. However, these factors were only present in early enrolled patients and did not affect later enrolled patients. Baseline characteristics and amyloid-related imaging abnormalities did not contribute to the difference in results between the high-dose arms.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE
(2023)
Article
Clinical Neurology
Tharick A. A. Pascoal, Antoine Leuzy, Joseph Therriault, Mira Chamoun, Firoza Lussier, Cecile Tissot, Olof Strandberg, Sebastian Palmqvist, Erik Stomrud, Pamela C. L. Ferreira, Joao Pedro Ferrari-Souza, Ruben Smith, Andrea Lessa Benedet, Serge Gauthier, Oskar Hansson, Pedro Rosa-Neto
Summary: This study investigates the optimal combination of amyloid-beta/tau/neurodegeneration (A/T/N) biomarkers for the diagnosis of Alzheimer's disease (AD) dementia. The results show that the tau biomarkers perform as well as the complete A/T/N system in diagnosing AD dementia. Additionally, the use of A or T neuroimaging biomarkers alone is equally effective in differentiating AD dementia from non-AD neurodegenerative diseases compared to using the complete A/T/N system.
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING
(2023)
Article
Psychiatry
Dhamidhu Eratne, Matthew Kang, Charles Malpas, Steve Simpson-Yap, Courtney Lewis, Christa Dang, Jasleen Grewal, Amy Coe, Hannah Dobson, Michael Keem, Wei-Hsuan Chiu, Tomas Kalincik, Suyi Ooi, David Darby, Amy Brodtmann, Oskar Hansson, Shorena Janelidze, Kaj Blennow, Henrik Zetterberg, Adam Walker, Olivia Dean, Michael Berk, Cassandra Wannan, Christos Pantelis, Samantha M. Loi, Mark Walterfang, Samuel F. Berkovic, Alexander F. Santillo, Dennis Velakoulis, MiND Study Grp
Summary: This study investigated the diagnostic utility of blood biomarkers of neuronal injury, specifically neurofilament light, in differentiating neurodegenerative disorders from primary psychiatric disorders (PPD). The results showed that neurofilament light could accurately distinguish behavioral variant frontotemporal dementia (bvFTD) from PPD. Large reference data sets and models were used to interpret individual levels, and slightly higher neurofilament light levels were found in bipolar affective disorder (BPAD) compared to controls and treatment-resistant schizophrenia (TRS).
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
(2023)
Article
Immunology
Jing Hua Zhao, David Stacey, Niclas Eriksson, Erin Macdonald-Dunlop, Asa K. Hedman, Anette Kalnapenkis, Stefan Enroth, Domenico Cozzetto, Jonathan Digby-Bell, Jonathan Marten, Lasse Folkersen, Christian Herder, Lina Jonsson, Sarah E. Bergen, Christian Gieger, Elise J. Needham, Praveen Surendran, Andres Metspalu, Lili Milani, Reedik Magi, Mari Nelis, Georgi Hudjasov, Dirk S. Paul, Ozren Polasek, Barbara Thorand, Harald Grallert, Michael Roden, Urmo Vosa, Tonu Esko, Caroline Hayward, Asa Johansson, Ulf Gyllensten, Nick Powell, Oskar Hansson, Niklas Mattsson-Carlgren, Peter K. Joshi, John Danesh, Leonid Padyukov, Lars Klareskog, Mikael Landen, James F. Wilson, Agneta Siegbahn, Lars Wallentin, Anders Malarstig, Adam S. Butterworth, James E. Peters
Summary: In this study, the authors conducted a genome-wide protein quantitative trait locus (pQTL) study to identify genetic influences on inflammation-related plasma proteins. They found 180 pQTLs and integrated the data with eQTL and disease genome-wide association studies to gain insight into pathogenesis and identified lymphotoxin-alpha in multiple sclerosis. Mendelian randomization (MR) analysis revealed shared and distinct effects of specific proteins across immune-mediated diseases, including CD40's contradictory effects on rheumatoid arthritis and multiple sclerosis. MR also implicated CXCL5 in the etiology of ulcerative colitis.
Article
Biochemistry & Molecular Biology
Sebastian Palmqvist, Marcello Rossi, Sara Hall, Corinne Quadalti, Niklas Mattsson-Carlgren, Sofia Dellavalle, Pontus Tideman, Joana B. Pereira, Maria H. Nilsson, Angela Mammana, Shorena Janelidze, Simone Baiardi, Erik Stomrud, Piero Parchi, Oskar Hansson
Summary: A long-term study reveals that Lewy body pathology in clinically unimpaired individuals is associated with worse smell and cognitive functions, as well as predicts cognitive decline and progression to Parkinson's disease or dementia with Lewy bodies. The study also found that α-synuclein aggregates have negative effects on cognition and memory, while tau pathology has similar effects but less pronounced for β-amyloid. Participants with both Lewy body and Alzheimer's disease pathology exhibited faster cognitive decline. These findings have implications for prognosis, recruitment, and outcome measures in preclinical Lewy body disease and early Alzheimer's disease trials.
Article
Biochemistry & Molecular Biology
Kanta Horie, Gemma Salvado, Nicolas R. Barthelemy, Shorena Janelidze, Yan Li, Yingxin He, Benjamin Saef, Charles D. Chen, Hong Jiang, Olof Strandberg, Alexa Pichet Binette, Sebastian Palmqvist, Chihiro Sato, Pallavi Sachdev, Akihiko Koyama, Brian A. Gordon, Tammie L. S. Benzinger, David M. Holtzman, John C. Morris, Niklas Mattsson-Carlgren, Erik Stomrud, Rik Ossenkoppele, Suzanne E. Schindler, Oskar Hansson, Randall J. Bateman
Summary: Aggregated insoluble tau is a defining feature of Alzheimer's disease, and there is a need for specific fluid biomarkers to track these tau aggregates. However, current fluid biomarkers are not specific enough. Researchers have identified a new cerebrospinal fluid biomarker, MTBR-tau243, which is specific for insoluble tau aggregates and shows strong associations with tau-positron emission tomography and cognitive measures.
Article
Biochemistry & Molecular Biology
Corinne Quadalti, Sebastian Palmqvist, Sara Hall, Marcello Rossi, Angela Mammana, Shorena Janelidze, Sofia Dellavalle, Niklas Mattsson-Carlgren, Simone Baiardi, Erik Stomrud, Oskar Hansson, Piero Parchi
Summary: Prospective and longitudinal analyses of patients with cognitive impairment revealed that the in vivo detection of Lewy body pathology is independently associated with hallucinations, worse attention/executive, visuospatial and motor function, and predicted future cognitive decline. LB pathology has clinical effects in patients with cognitive impairment, especially in those coexisting with AD pathology. LB pathology is associated with faster cognitive decline, regardless of AD pathology and cognitive stage, which suggests that LB status is a better predictor for clinical trajectories than AD biomarkers and clinical diagnosis.
Article
Clinical Neurology
D. Angioni, O. Hansson, R. J. Bateman, C. Rabe, M. Toloue, J. B. Braunstein, S. Agus, J. R. Sims, T. Bittner, M. C. Carrillo, H. Fillit, C. L. Masters, S. Salloway, P. Aisen, M. Weiner, B. Vellas, S. Gauthier, Mohammad EU US CTAD Task force, John Alam, Alicia Algeciras-Schimnich, Sandrine Andrieu, Clive Ballard, Amos Baruch, Richard Batrla, Monika Baudler, Joanne Bell, Sasha Bozeat, Dawn Brooks, Tricia Brooks, Szofia Bullain, Jan Burmeister, Min Cho, Emily Collins, Gavin Cook, Jeffrey Cummings, Chris Dague, Susan De Santi, Rachelle Doody, Billy Dunn, Michael Egan, Sven Eriksson, Rianne Esquivel, Tom Fagan, Phyllis Ferrell, Michela Gallagher, Anna-Kaija Groenblad, Avis Hains, Harald Hampel, Nanco Hefting, Suzanne Hendrix, Carole Ho, Helen Hu, Zahinoor Ismail, Daryl Jones, Gene Kinney, Paul Kinnon, Ricky Kurzman, Lars Lannfelt, John Lawson, Nathalie LeBastard, Valerie Legrand, Nicole Lewandowski, Carine Lim, Costantine Lyketsos, Donna Masterman, Ming Lu, Mark Mintun, Jose Luis Molinuevo, Cecilia Monteiro, Bradford Navia, Tomas Odergren, Gunilla Osswald, Lewis Penny, Michael Pontecorvo, Anton Porsteinsson, Rema Raman, Gesine Respondek, Larisa Reyderman, Sharon Rogers, Paul Rosenberg, Sharon Rosenzweig-Lipson, Mark Roskey, Rubel Carrie, Ziad Saad, Rachel Schindler, Dennis Selkoe, Melanie Shulman, Kaycee Sink, Lisa Sipe, Daniel Skovronsky, Elizabeth Somers, Maria Soto, Johannes Streffer, Pedro Such, Joyce Suhy, Jacques Touchon, Manu Vandijck, Anne White, David Wilson, Wagner Zago, Jin Zhou
Summary: In randomized clinical trials for Alzheimer's Disease, CSF and PET biomarkers are currently used for detection and monitoring of the disease. However, using less resource-intensive plasma biomarkers, such as blood-based markers, could potentially improve the design and conduct of these trials. It is still uncertain if the available data on blood-based markers are strong enough to replace CSF and PET biomarkers in RCTs as entry criteria and monitoring tools.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE
(2023)
Correction
Clinical Neurology
Emma Borland, Chris Edgar, Erik Stomrud, Nicholas Cullen, Oskar Hansson, Sebastian Palmqvist
Article
Cell Biology
Oskar Hansson, Kaj Blennow, Henrik Zetterberg, Jeffrey Dage
Summary: Blood-based biomarkers have the potential to greatly improve the diagnosis and prognosis of Alzheimer's disease (AD) in clinical practice. Assays for measuring phosphorylated tau (p-tau) in plasma have high diagnostic accuracy in distinguishing AD from other neurodegenerative diseases in patients with cognitive impairment. These biomarkers can also predict the future development of AD dementia in patients with mild cognitive complaints. The use of such blood-based biomarkers can reduce the need for more costly investigations and facilitate identification of individuals with pre-symptomatic AD in clinical trials.
Correction
Neurosciences
Luke Harper, Olof Lindberg, Martina Bocchetta, Emily G. Todd, Olof Strandberg, Danielle van Westen, Erik Stomrud, Maria Landqvist WaldO, Lars-Olof Wahlund, Oskar Hansson, Jonathan D. Rohrer, Alexander Santillo